Cited by 508Immune cells in cancerSarcoma Diagnosis and TreatmentCancer Cells and Metastasis

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents

Buddingh, Emilie P., Kuijjer, Marieke L., Duim, Ronald A.J., Bürger, Horst, Agelopoulos, Konstantin, Myklebost, Ola, Serra, Massimo, Mertens, Fredrik, Hogendoorn, Pancras C.W., Lankester, Arjan C., Cleton-Jansen, Anne-Marie·2011·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-10-2047

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: High-grade osteosarcoma is a malignant primary bone tumor with a peak incidence in adolescence. Overall survival (OS) of patients with resectable metastatic disease is approximately 20%. The exact mechanisms of development of metastases in osteosarcoma remain unclear. Most studies focus on tumor cells, but it is increasingly evident that stroma plays an important role in tumorigenesis and metastasis. We investigated the development of metastasis by studying tumor cells and their stromal context. Experimental Design: To identify gene signatures playing a role in metastasis, we carried out genome-wide gene expression profiling on prechemotherapy biopsies of patients who did (n = 34) and patients who did not (n = 19) develop metastases within 5 years. Immunohistochemistry (IHC) was performed on pretreatment biopsies from 2 additional cohorts (n = 63 and n = 16) and corresponding postchemotherapy resections and metastases. Results: A total of 118/132 differentially expressed genes were upregulated in patients without metastases. Remarkably, almost half of these upregulated genes had immunological functions, particularly related to macrophages. Macrophage-associated genes were expressed by infiltrating cells and not by osteosarcoma cells. Tumor-associated macrophages (TAM) were quantified with IHC and associated with significantly better overall survival (OS) in the additional patient cohorts. Osteosarcoma samples contained both M1- (CD14/HLA-DRα positive) and M2-type TAMs (CD14/CD163 positive and association with angiogenesis). Conclusions: In contrast to most other tumor types, TAMs are associated with reduced metastasis and improved survival in high-grade osteosarcoma. This study provides a biological rationale for the adjuvant treatment of high-grade osteosarcoma patients with macrophage activating agents, such as muramyl tripeptide. Clin Cancer Res; 17(8); 2110–9. ©2011 AACR.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-2047

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,082
Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,349
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Bielack, S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.776 · Cited by 2,391
Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression
Martinez, F. O., Gordon, S., Locati, M., & Mantovani, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.7303 · Cited by 2,125
lumi : a pipeline for processing Illumina microarray
Du, P., Kibbe, W. A., & Lin, S. M. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn224 · Cited by 2,028
How dying cells alert the immune system to danger
Kono, H., & Rock, K. L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2215 · Cited by 1,737
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712

Show all 45 references

Research works printed but not linked: 2

Raymond, 2002, Conventional osteosarcoma, 264
2005, R: a language and environment for statistical computing, reference index version 2.9.0.

Sorted by citations

Items 401–500 of 504

Transcriptomic analysis reveals TME-mediated macrophage IFIT1 upregulation and CX3CR1 suppression drive osteosarcoma progression
Wang, K., He, H., Liang, J., Su, Y., Zhao, J., & Liu, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1686854 · Cited by 1
A PCD-related prognostic signature and the oncogenic role of TRIM8 in osteosarcoma progression
Zhang, L., Ou, X., Wang, Q., & Shi, S. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07305-5 · Cited by 1
Immunotherapeutic advances for the treatment of osteosarcoma, driven by studies in pet dogs with spontaneous disease
Edmunds, G. L., & Mason, N. J. (2026) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2026.12 · Cited by 1
Osteosarcoma as a communication-driven disease: redefining tumor–bone signaling networks as therapeutic targets
Ricciardi, G., Fiorentino, V., Tralongo, P., Lentini, M., Pepe, L. R., Zuccalà, V., Ballato, M., Giuffrè, G., Ieni, A., Zampogna, B., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1823738 · Cited by 1
Macrophages and pathophysiology of bone cancers
Sousa, S., & Määttä, J. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00009-1 · Cited by 1
The anoikis-related gene signature predicts survival and correlates with immune infiltration in osteosarcoma
Li, J., Wang, H., Wu, F., Yao, J., Zhu, H., & Zhang, M. (2024) · Aging · doi:10.18632/aging.205411 · Cited by 1
Unraveling the PANoptosis Landscape in Osteosarcoma: A Single‐Cell Sequencing and Machine Learning Approach to Prognostic Modeling and Tumor Microenvironment Analysis
Gui, X.-Y., Wang, J., Zhang, Y., Tang, Z., & Zhu, Z. (2025) · International Journal of Genomics · doi:10.1155/ijog/6915258 · Cited by 1
Personalized Cancer Therapy for Soft Tissue Sarcomas: Progress and Pitfalls
Myklebost, O. (2015) · Personalized Medicine · doi:10.2217/pme.15.20 · Cited by 1
Self-citation
Cytokines and bone cancers
Royer, B. B.-L., & Blanchard, F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00010-8 · Cited by 1
The immune environment of bone sarcomas
Richert, I., & Dutour, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821666-8.00070-0 · Cited by 3
CLEC5a-directed bispecific antibody for effective cellular phagocytosis
Kedage, V., Ellerman, D. A., Fei, M., Liang, W., Zhang, G., Cheng, E., Zhang, J., Chen, Y., Huang, H., Lee, W. P., et al. (2022) · mAbs · doi:10.1080/19420862.2022.2040083 · Cited by 1
Tumour mutational burden and immune-cell infiltration in cervical squamous cell carcinoma
(2022) · European Journal of Gynaecological Oncology · doi:10.22514/ejgo.2022.016 · Cited by 1
Identification of Two Novel Immune Subtypes Characterized by Distinct Prognosis and Tumor Microenvironment in Osteosarcoma
Yao, S., Deng, M., Du, X., Chen, Q., & Huang, R. (2022) · Journal of Immunology Research · doi:10.1155/2022/2181525 · Cited by 1
Integrated Analysis of Multi-Omics Data to Establish a Hypoxia-Related Prognostic Model in Osteosarcoma
Ye, T., Zhang, X., & Zhou, Y. (2022) · Evolutionary Bioinformatics · doi:10.1177/11769343221128537 · Cited by 1
Identification of a novel MYC target gene set signature for predicting the prognosis of osteosarcoma patients
Gong, D., Zhao, Q., Liu, J., Zhao, S., Yi, C., Lv, J., Yu, H., Bian, E., & Tian, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1169430 · Cited by 1
A potential prognostic prediction model for metastatic osteosarcoma based on bioinformatics analysis
Wang, Y., Ming, G.-F., & Bohua, G. A. O. (2023) · Acta Orthopaedica Belgica · doi:10.52628/89.2.10491 · Cited by 1
Osteosarcoma therapy: what is the way forward?
Andrews, N. A. (2013) · IBMS BoneKEy · doi:10.1038/bonekey.2013.106 · Cited by 1
Microambiente imune no carcinoma papilífero de tireoide e sua relação com fatores prognósticos clínico-patológicos e sobrevida
Lira, R. B. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-06012017-092200 · Cited by 1
XXXVIII Congresso Nazionale AIEOP, Roma 9-11 giugno 2013 - Relazioni
Infermieristiche, R. S. P. M. E. (2013) · Pediatric Reports · doi:10.4081/2013.s1.rel · Cited by 1
Implication of immune system in chondrosarcoma progression and therapeutic response : Could immunotherapy play a role in chondrosarcoma treatment ?
Simard, F. A. (2016) · theses.fr (ABES) · doi:10.70675/69d89730z693dz4330za234z5f8e56bde8d7 · Cited by 1
Resolving mechanisms of apoptosis in response to WNT3A in Melanoma
Conrad, W. H. (2012) · ResearchWorks at the University of Washington (University of Washington)
Le nuove frontiere della ricerca in oncologia del sistema muscolo-scheletrico
Healey, J. H. (2011) · LO SCALPELLO-OTODI Educational · doi:10.1007/s11639-011-0119-1
Biology of Osteosarcoma
Serra, M. (2013) · Springer eBooks · doi:10.1007/978-3-319-01748-8_43
Self-citation
Osteosarcoma Biomarkers Discovery Using “Omics” Approaches
Bernardini, G., Orlandini, M., Galvagni, F., & Santucci, A. (2015) · Biomarkers in disease · doi:10.1007/978-94-007-7745-3_17-1
Monoclonal Antibodies Targeting the Immune System
Minard‐Colin, V. (2017) · Springer eBooks · doi:10.1007/978-3-319-43486-5_7
Immune Biomarkers in Paediatric Malignancies
Semeraro, M., Pasqualini, C., & Chaput, N. (2017) · Springer eBooks · doi:10.1007/978-3-319-43486-5_12
Characterization of the Effects of Bacteria-Induced Inflammation and Hyperthermia Therapy on Monocytes and Macrophages in Osteosarcoma.
Tuohy, J. L. (2017) · NCSU Libraries Repository (North Carolina State University Libraries)
Convergence of Bioengineering, Orthopaedics and Tumour Biology to Develop and Validate Humanized Rodent Models for Primary Bone Tumour Research
Wagner, F. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.116423
Significance of incorporation of DNMT1 and HLA-DRα with TNM staging in patients with hepatocellular carcinoma after curative resection.
Tang, H., Lu, W., Yang, Z., Chen, Y., Wang, J., Lu, S., & Jiang, K. (2017) · PubMed Central
Histone Deacetylase-2 Serves as an Independent Prognostic Indicator in OsteosarcomaPreprint
Wang, D., Ye, Y., Qu, T., Zhao, Z., Gu, Z., Zheng, J., & Hu, X. (2020) · Research Square · doi:10.21203/rs.3.rs-127806/v1
Peer Review #1 of "Gene signatures with predictive and prognostic survival values in human osteosarcoma (v0.2)"
(2021) · PeerJ · doi:10.7287/peerj.10633v0.2/reviews/1
Peer Review #1 of "Gene signatures with predictive and prognostic survival values in human osteosarcoma (v0.1)"
(2021) · PeerJ · doi:10.7287/peerj.10633v0.1/reviews/1
Monitoring the Systemic Immune System to Understand and Improve the Efficacy of Immunotherapy for Metastatic Osteosarcoma
Markel, J. (2020) · doi:10.33915/etd.7770
Macrophages and pathophysiology of bone cancers
Sousa, S., & Määttä, J. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821666-8.00056-6
Macrophages and Tumor Development
Ostrand‐Rosenberg, S. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8056-4_6
Peer Review #2 of "Gene signatures with predictive and prognostic survival values in human osteosarcoma (v0.1)"
(2021) · PeerJ · doi:10.7287/peerj.10633v0.1/reviews/2
Osteosarcoma Biomarkers Discovery Using “Omics” Approaches
Bernardini, G., Orlandini, M., Galvagni, F., & Santucci, A. (2017) · Biomarkers in disease · doi:10.1007/978-94-007-7693-7_17
Oncolytic adenovirus Delta-24- RGD engineered to express 4-1BBL or OX40L as therapeutic approach for diffuse intrinsic pontine gliomas
Laspidea, V. (2022) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · doi:10.15581/10171/65228
Supplementary data from Tenascin-C Promotes Tumor Cell Migration and Metastasis through Integrin α9β1–Mediated YAP Inhibition
Sun, Z., Schwenzer, A., Rupp, T., Murdamoothoo, D., Vegliante, R., Lefèbvre, O., Klein, A., Hussenet, T., & Orend, G. (2023) · doi:10.1158/0008-5472.22417017
Data from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
Cillo, A. R., Mukherjee, E., Bailey, N. G., Onkar, S., Daley, J. D., Salgado, C. M., Li, X., Liu, D., Ranganathan, S., Burgess, M. A., et al. (2023) · doi:10.1158/1078-0432.c.6532980
To construct a prognostic model and identify target gene of macrophage polarization by machine learning for predicting immune responses in osteosarcoma and pan- cancerPreprint
Wang, D., Peng, Y., Tong, Z., Li, Z., Huang, L., Zeng, J., Li, J., Miao, J., & Chen, S. (2023) · Research Square · doi:10.21203/rs.3.rs-3116741/v1
Additional file 1 of Construction of an integrated human osteosarcoma database, HOsDb, based on literature mining, microarray analysis, and database retrieval
Sun, Y., Wang, L., Li, C., Gu, R., Zang, W., Song, W., & Xia, P. (2020) · Figshare · doi:10.6084/m9.figshare.12262235
Causal association of immune cell phenotypes with osteosarcoma and the mediation role of blood metabolites: A two-steps, two-samples Mendelian randomization studyPreprint
Niu, C., Xu, Q., Wang, W., Li, H., Ding, Q., Guo, L., Zeng, P., & Liu, J. (2024) · Research Square · doi:10.21203/rs.3.rs-4454204/v1
Identification and validation of disulfidptosis-related signature to evaluate clinical outcomes, immune infiltration and drug sensitivity in osteosarcomaPreprint
Zhao, Y., Su, X., Teng, M., Ru, H., lu, Z., Zhang, Y., Zhang, Y., & Zhang, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-4426108/v1
Developing a PANoptosis Signature: Identification of Unique Immunotherapeutic Candidates for OsteosarcomaPreprint
Zhou, S., Zhou, J., Li, L., Song, B., Cheng, Y., Xie, W., Zhao, Y., Yang, F., Zhuang, Q., & Zhang, Q. (2024) · Research Square · doi:10.21203/rs.3.rs-4488764/v1
The prognostic value of ubiquitin/ubiquitin-like-related genes along with immune cell infiltration and clinicopathological features in osteosarcoma
Wen, J., Wan, L., Chen, W., & Dong, X. (2024) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-024-04781-1
β-Lapachone NLCs — Repolarizing tumor-associated macrophages for osteosarcoma therapy
Díaz‐Rodríguez, P., Martínez-Borrajo, R., Lorenzo-Lorenzo, A. A., & Landín, M. (2025) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.20960/revosteoporosmetabminer.00082
Constructing a ferroptosis-related prognostic model for osteosarcoma based on scRNA-seq dataset and WGCNA analysis
Yi, H. L. (2025) · International Journal of Clinical and Experimental Pathology · doi:10.62347/qvon7675
Deubiquitinase Genes as Prognostic Biomarkers in Osteosarcoma: Insights From Single‐Cell Sequencing and Machine Learning–Based Prognostic Modeling
Zhang, M., Cheng, C., & Liu, G. (2025) · International Journal of Genomics · doi:10.1155/ijog/7932638
Creatine kinase B, a downstream effector of c-Myb, controls migration of osteosarcoma cells via regulation of N-cadherin
Pokludová, J., Lapčík, P., Zambo, I. S., Kohoutek, J., Zapletalová, D., Múdrý, P., Adámková, D., Červinka, J., Loja, T., Lexa, M., et al. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04087-0
Additional file 1 of Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma
Cascini, C., Ratti, C., Botti, L., Parma, B., Cancila, V., Salvaggio, A., Meazza, C., Tripodo, C., Colombo, M. P., & Chiodoni, C. (2023) · Figshare · doi:10.6084/m9.figshare.23583492
Additional file 5 of Integration of single-cell sequencing and bulk expression data reveals chemokine signaling pathway in proliferating cells is associated with the survival outcome of osteosarcoma
Yu, L., Hongyu, S., & Yuxi, C. (2023) · Figshare · doi:10.6084/m9.figshare.23849537
Additional file 3 of Integration of single-cell sequencing and bulk expression data reveals chemokine signaling pathway in proliferating cells is associated with the survival outcome of osteosarcoma
Yu, L., Hongyu, S., & Yuxi, C. (2023) · Figshare · doi:10.6084/m9.figshare.23849531
Additional file 4 of Integration of single-cell sequencing and bulk expression data reveals chemokine signaling pathway in proliferating cells is associated with the survival outcome of osteosarcoma
Yu, L., Hongyu, S., & Yuxi, C. (2023) · Figshare · doi:10.6084/m9.figshare.23849534
Additional file 2 of The prognostic value of ubiquitin/ubiquitin-like-related genes along with immune cell infiltration and clinicopathological features in osteosarcoma
Wen, J., Wan, L., Chen, W., & Dong, X. (2024) · Figshare · doi:10.6084/m9.figshare.26734449
Additional file 2 of Identification and verification of a BMPs-related gene signature for osteosarcoma prognosis prediction
Xie, L., Zeng, J., & He, M. (2023) · Figshare · doi:10.6084/m9.figshare.22599640
Additional file 3 of The prognostic value of ubiquitin/ubiquitin-like-related genes along with immune cell infiltration and clinicopathological features in osteosarcoma
Wen, J., Wan, L., Chen, W., & Dong, X. (2024) · Figshare · doi:10.6084/m9.figshare.26734452
Additional file 6 of Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma
Cascini, C., Ratti, C., Botti, L., Parma, B., Cancila, V., Salvaggio, A., Meazza, C., Tripodo, C., Colombo, M. P., & Chiodoni, C. (2023) · Figshare · doi:10.6084/m9.figshare.23583507
Additional file 5 of Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma
Cascini, C., Ratti, C., Botti, L., Parma, B., Cancila, V., Salvaggio, A., Meazza, C., Tripodo, C., Colombo, M. P., & Chiodoni, C. (2023) · Figshare · doi:10.6084/m9.figshare.23583504
Additional file 1 of Integration of single-cell sequencing and bulk expression data reveals chemokine signaling pathway in proliferating cells is associated with the survival outcome of osteosarcoma
Yu, L., Hongyu, S., & Yuxi, C. (2023) · Figshare · doi:10.6084/m9.figshare.23849525
Additional file 2 of Integration of single-cell sequencing and bulk expression data reveals chemokine signaling pathway in proliferating cells is associated with the survival outcome of osteosarcoma
Yu, L., Hongyu, S., & Yuxi, C. (2023) · Figshare · doi:10.6084/m9.figshare.23849528
Additional file 3 of Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma
Cascini, C., Ratti, C., Botti, L., Parma, B., Cancila, V., Salvaggio, A., Meazza, C., Tripodo, C., Colombo, M. P., & Chiodoni, C. (2023) · Figshare · doi:10.6084/m9.figshare.23583498
Additional file 4 of Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma
Cascini, C., Ratti, C., Botti, L., Parma, B., Cancila, V., Salvaggio, A., Meazza, C., Tripodo, C., Colombo, M. P., & Chiodoni, C. (2023) · Figshare · doi:10.6084/m9.figshare.23583501
Additional file 4 of The prognostic value of ubiquitin/ubiquitin-like-related genes along with immune cell infiltration and clinicopathological features in osteosarcoma
Wen, J., Wan, L., Chen, W., & Dong, X. (2024) · Figshare · doi:10.6084/m9.figshare.26734455
Additional file 2 of Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma
Cascini, C., Ratti, C., Botti, L., Parma, B., Cancila, V., Salvaggio, A., Meazza, C., Tripodo, C., Colombo, M. P., & Chiodoni, C. (2023) · Figshare · doi:10.6084/m9.figshare.23583495
Additional file 1 of Identification and verification of a BMPs-related gene signature for osteosarcoma prognosis prediction
Xie, L., Zeng, J., & He, M. (2023) · Figshare · doi:10.6084/m9.figshare.22599637
Additional file 1 of Macrophages-derived exosomal lncRNA LIFR-AS1 promotes osteosarcoma cell progression via miR-29a/NFIA axis
Zhang, H., Yu, Y., Wang, J., Han, Y., Ren, T., Huang, Y., Chen, C., Huang, Q., Wang, W., Niu, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361804
Additional file 1 of A tumor microenvironment-based prognostic index for osteosarcoma
Wu, C., Gong, S., Duan, Y., Deng, C., Kallendrusch, S., Berninghausen, L. K., Osterhoff, G., & Schopow, N. (2023) · Figshare · doi:10.6084/m9.figshare.22631604
Additional file 1 of RNA adenosine modifications related to prognosis and immune infiltration in osteosarcoma
Chen, S., Zeng, J., Huang, L., Peng, Y., Yan, Z., Zhang, A., Zhao, X., Li, J., Zhou, Z., Wang, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19767727
Additional file 3 of Identification and verification of a BMPs-related gene signature for osteosarcoma prognosis prediction
Xie, L., Zeng, J., & He, M. (2023) · Figshare · doi:10.6084/m9.figshare.22599643
Additional file 1 of A novel risk score model based on eight genes and a nomogram for predicting overall survival of patients with osteosarcoma
Wu, G., & Zhang, M. (2020) · Figshare · doi:10.6084/m9.figshare.12364934
Additional file 1 of The prognostic value of ubiquitin/ubiquitin-like-related genes along with immune cell infiltration and clinicopathological features in osteosarcoma
Wen, J., Wan, L., Chen, W., & Dong, X. (2024) · Figshare · doi:10.6084/m9.figshare.26734446
Evaluating the causal effects of circulating plasma proteins on the risk of malignant neoplasms of bone and articular cartilage
Wang, Y., Zhou, R., Wu, Z., & Lv, Z. (2026) · Journal of International Medical Research · doi:10.1177/03000605261416727
Utilizing bulk and single-cell RNA sequencing to identify potential biomarkers linked to angiogenesis and integrated stress response in chondrosarcoma
Li, S., Zhao, J., Qin, Q., Huang, H., Liu, D., Liu, Y., Peng, D., Yu, H., Jing, H., Wu, Y., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-40800-3
Prognostic and Immunomodulatory Roles of BNIP3 in Osteosarcoma Revealed by Integrated Single‐Cell and Bulk Transcriptomic Profiling
Li, J., Wang, W., Li, L., & Yu, K. (2026) · International Journal of Genomics · doi:10.1155/ijog/9272264
Effets de la combinaison de la doxorubicine et de l’interférence avec la NTN1 sur la progression tumorale et l’infiltrat immunitaire de l’ostéosarcome
Monchanin, M. (2017) · theses.fr (ABES) · doi:10.70675/4fb543d1z0d27z4522zabecz114e69536773
Immuno-modulatory functions of tenascin-C in a tumor progression model
Murdamoothoo, D. (2018) · theses.fr (ABES) · doi:10.70675/0ebddce2z280az4c92z9177z76ee60326851
Rôle de la voie de signalisation Hippo dans le développement des ostéosarcomes
Morice, S. (2019) · theses.fr (ABES) · doi:10.70675/32829b80z5982z4f52z949bz98b3ed38b7c0
Développement et caractérisation de NanoAssemblages aux propriétés théranostiques : Etude dans le microenvironnement tumoral
Blondy, T. (2018) · theses.fr (ABES) · doi:10.70675/4722c8dbz3291z4ab3z9561za803c5f1a654
Les macrophages au sein du microenvironnement tumoral : étude et modulation des mécanismes moléculaires et cellulaires de la réponse anti-tumorale au cours de carcinoses péritonéales
Prat, M. (2019) · theses.fr (ABES) · doi:10.70675/606044acz15f8z45d8z9566ze0de40cff550
Rôle de l'hypoxie dans l'immunothérapie des ostéosarcomes pédiatriques ciblant le GD2
Pierrevelcin, M. (2021) · theses.fr (ABES) · doi:10.70675/9d2c6f5dzb23ez4823z9c0fze8ea3c9c8bc7
Utilisation de miRNAs thérapeutiques pour traiter les chondrosarcomes et les ostéosarcomes
Veys, C. (2021) · theses.fr (ABES) · doi:10.70675/7a59188ez7981z4d53za4fdz22a6b5deaaad
Targeting CD3L1-NRP2 disarms myeloid-driven tumor immune evasion
Deng, S., Fang, Y., Xue, J., Wang, R., Zhou, X., Li, C., Li, N., Wang, S., Zhang, Y., Wang, H., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00451-3
M2 macrophage-associated factors for constructing a prognostic model for osteosarcoma
Han, J. (2026) · Medicine · doi:10.1097/md.0000000000048626
Predictive value of an ICD-associated DAMP gene signature for survival and immunotherapy response in osteosarcoma patients
Jin, H., Zhang, X., Li, H., & Li, X. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103632
PSIP1 Orchestrates Immune Escape in Osteosarcoma: Insights From Single‐Cell Analysis and Implications for Immunotherapy Resistance
Liu, S., Yan, H., Ku, W., & Liu, G. (2026) · International Journal of Genomics · doi:10.1155/ijog/2344901
An Epithelial–Mesenchymal Transition–Driven Transcriptional Index Stratifies Immunosuppression and Therapeutic Resistance in Bone Malignancies
Pang, L., Hua, Y., Chen, Z., & Wu, G. (2026) · International Journal of Genomics · doi:10.1155/ijog/6315219
Genomic landscape and tumor immune microenvironment of osteosarcoma: Bridging mechanistic insights to precision therapeutics
Yang, C., Yu, Y., Wang, Y., Cai, Z., Zhao, Y., Ma, H., Xu, J., Zhu, H., Ren, T., Tang, X., et al. (2026) · Bone Reports · doi:10.1016/j.bonr.2026.101930 · Cited by 1
Juglone induces GSDME axis pyroptosis in osteosarcoma cells via the JNK/P38 MAPK pathway
Zhao, J., Zhao, X., Lu, Y., Wang, H., Zhang, Y., Wang, Y., Xing, L., Guo, Y., Peng, P., Zhang, W., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-58482-2
Single-cell fixed RNA profiling of the osteosarcoma clinical Spectrum identifies ADAMTS12 and RNASE1 as key drivers of the metastatic niche
Khanh, N. V., Dũng, T. T., Hai, H., Sang, N. T. Q., Thanh, T. D., Quang, D. M., Ha, N. T., Chi, N. B. T., Anh, P. T., Duc, P. M., et al. (2026) · Journal of bone oncology · doi:10.1016/j.jbo.2026.100781
An Auto-RS Signature for Prognostic Stratification and Drug Sensitivity Prediction in Osteosarcoma
Liu, Q., Zhou, C., Xu, K., Zhu, Q., Lu, J., Zhang, C., Xie, W., Fang, G., Chen, X. Z., Tian, D., et al. (2026) · Genes · doi:10.3390/genes17070737
A Transient Receptor Potential-related Gene Model for the Prognostic Assessment and Drug Sensitivity Prediction in Osteosarcoma
Li, X., Zhang, M., Xu, Z., Wang, W., & Li, P. (2026) · Current Medicinal Chemistry · doi:10.2174/0109298673510271260627113203
Integrated Bulk and Single-Cell Transcriptomics Reveals the C3–C3AR1 Axis as a Candidate Mediator of Coagulome-Immune Crosstalk in Osteosarcoma
Mu, J., Wang, Y., Liu, H., He, X., Li, Z., Lu, M., Tang, F., Luo, Y., Zhou, Y., Li, M., et al. (2026) · Biomedicines · doi:10.3390/biomedicines14081686
Proteome-wide Multi-omics Profiling of Osteosarcoma Transcription Factor Networks
Thang, N. X., Martinsen, E., Abdelhalim, M., Tran, T. T., Ledsaak, M., Rogne, M., Thiede, B., & Eskeland, R. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2026.169959
Collateral sensitivities with predictive signatures emerge in a novel model of evolved chemoresistance in osteosarcomaPreprint
Burke, Z. D. C., Lin‐Rahardja, K., Mandel, G., Imamura, J., Durmaz, A., Nowak, E., Hitomi, M., & Scott, J. G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.10.743977
TLR7 Agonist Nanomedicine Suppresses Lung Metastasis of Osteosarcoma by Remodeling the Immune Microenvironment
Zhang, X., Zeng, H., Qin, F., Wei, Y., Wan, D., & Wei, X. (2026) · MedComm – Oncology · doi:10.1002/mog2.70093
The Osteosarcoma Tumor Microenvironment: From Cellular Interactions to Advanced Preclinical Models
Feo, G. D., Paola, A. D., Domenico, O. D., Argenziano, L., Pota, E., Pinto, D. D., Martino, M. D., Marrapodi, M. M., & Rossi, F. (2026) · Cancers · doi:10.3390/cancers18182909
Osteosarcoma Across the Age Spectrum: Why Outcomes Diverge and Trials Must Adapt
Collins, S. H., & Matushansky, I. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187017
Biomarker-guided immunotherapy in osteosarcoma: from immune microenvironment profiling to patient stratification and combination strategies
Li, Q. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1987146
Integrative Single‐Cell and Bulk Transcriptomics Identifies a Proliferative Malignant State and Supports a Functional Contribution of TROAP in Osteosarcoma
Jiao, P., Chen, X., Wei, H., 孙志华, Lu, M., Bai, Y., Zhang, W., & Wang, D. (2026) · International Journal of Genomics · doi:10.1155/ijog/1407947

Authors: Buddingh, E. P., Kuijjer, M. L., Duim, R. A. J., Bürger, H., Agelopoulos, K., Myklebost, O., Serra, M., Mertens, F., Hogendoorn, P. C. W., Lankester, A. C., & Cleton-Jansen, A.-M.
Affiliations: Oslo University Hospital (NO)
Authors' Affiliations: 1Department of Pediatrics; 2Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; 3Institute of Pathology; 4Department of Medicine, Hematology and Oncology, University of Münster, Münster, Germany; 5Department of Tumor Biology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; 6Laboratory of Experimental Oncology Research, Istituto Ortopedico Rizzoli, Bologna, Italy; and 7Department of Clinical Genetics, Lund University Hospital, Lund, Sweden
Corresponding author: Cleton-Jansen, Anne-Marie
ORCID: Buddingh, Emilie P.
Kuijjer, Marieke L.
Agelopoulos, Konstantin
Myklebost, Ola
Serra, Massimo
Mertens, Fredrik
Hogendoorn, Pancras C.W.
Lankester, Arjan C.
Cleton-Jansen, Anne-Marie
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2011-04-14
Volume: 17
Issue: 8
Pages: 2110-2119
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-10-2047
OpenAlex: W2106409672
Cited by: 508
References: 45
Citations by year: 2026: 27 · 2025: 45 · 2024: 48 · 2023: 63 · 2022: 47 · 2021: 54 · 2020: 50 · 2019: 24 · 2018: 20 · 2017: 36 · 2016: 24 · 2015: 17 · 2014: 15 · 2013: 13 · 2012: 18
FWCI: 7.52
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Leiden Repository (Leiden University) (submittedVersion)
Lund University Publications (Lund University) (submittedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords: high-grade osteosarcoma, tumor-infiltrating macrophages, metastasis suppression, tumor-associated macrophages, tumor stroma, gene expression profiling, overall survival, muramyl tripeptide, adjuvant therapy, CD14, CD163, angiogenesis
MeSH terms: Bone Neoplasms, Humans, Immunohistochemistry, Macrophages, Neoplasm Metastasis, Prognosis, Osteosarcoma, Time Factors, Cohort Studies, Gene Expression Regulation, Neoplastic, Reverse Transcriptase Polymerase Chain Reaction, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks